➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Johnson and Johnson
Merck
Colorcon
McKesson

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Claims for Patent: 7,795,026

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,795,026
Title:Methods for obtaining human embryoid body-derived cells
Abstract: The invention is directed to novel cells that are derived from human embryoid bodies. Such embryoid body-derived (EBD) cells are relatively uncommitted or progenitor (e.g., pluripotent) cells. EBD cells, while not immortal, display long-term proliferation in culture with a normal karyotype and can be cryopreserved and cloned. They can be efficiently transfected with retroviruses and lentivirus and genetically manipulated. Although they have a developmentally broad multilineage expression profile, they do not form tumors when injected into severe combined immunodeficiency (SCID) mice. As a result, EBD cells have a variety of uses, for example, in transplantation therapies.
Inventor(s): Shamblott; Michael J. (Baltimore, MD), Gearhart; John D. (Baltimore, MD)
Assignee: The Johns Hopkins University School of Medicine (Baltimore, MD)
Application Number:09/767,421
Patent Claims:1. A method of obtaining a human embryoid body derived (EBD) cell comprising: (a) culturing primordial germ cells in a media comprising human basic fibroblast growth factor and lacking leukemia inhibitory factor under conditions that allow formation of a solid or cystic embryoid body having a 3-dimensional morphology; (b) disaggregating the solid or cystic embryoid body under enzymatic conditions to provide a constituent cell or embryoid body derived (EBD) cell; and (c) culturing the EBD cell on a defined extracellular matrix, wherein the EBD cell forms disaggregated single cells upon dissociation from embryoid bodies (EB) and proliferates for at least 30 population doublings without being immortal under the conditions of step (a).

2. The method of claim 1 comprising selecting a single EBD cell from the EBD cells and culturing the single EBD cell to produce a clonal population of cells.

3. The method of claim 1 comprising culturing the EBD cell in a media selected from the group consisting of RPMI 1640 supplemented with 15% serum and media consisting essentially of hEGF, hydrocortisone, gentamicin, amphotericin-B, fetal bovine serum, VEGF, heparin, recombinant human IGF-1 and ascorbic acid.

4. The method of claim 3 comprising culturing the EBD cell in a media consisting essentially of hEGF, hydrocortisone, gentamicin, amphotericin-B, fetal bovine serum, VEGF, heparin, recombinant human IGF-1 and ascorbic acid.

5. The method of claim 1, wherein the matrix comprises one or more defined extracellular matrix components.

6. The method of claim 5, wherein the one or more defined extracellular matrix components are selected from the group consisting of collagen I and human extracellular matrix extract.

7. The method of claim 6, wherein the one or more defined extracellular matrix components are selected from the group consisting of collagen I and human extracellular matrix extract.

8. The method of claim 1 comprising culturing the EBD cells for at least 30 population doublings.

9. The method of obtaining a human EBD cell of claim 1, wherein the enzymatic conditions include collagenase, dispase, or both.

10. The method of claim 1, further comprising expanding the EBD cells on one or more defined extracellular matrix components.

11. The method of claim 10, wherein the one or more defined extracellular matrix components are selected from the group consisting of collagen I and human extracellular matrix extract.

Details for Patent 7,795,026

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04   Start Trial The Johns Hopkins University School of Medicine (Baltimore, MD) 2020-01-21 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Dow
Express Scripts
Colorcon
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.